Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rybrevant
Pharma
FDA approves J&J's new challenge to Tagrisso
Subcutaneous Rybrevant will be a better tool for J&J in its uphill fight against AstraZeneca’s Tagrisso in EGFR-mutated lung cancer.
Angus Liu
Dec 18, 2025 10:40am
AstraZeneca bolsters Tagrisso's case amid J&J rivalry
Sep 7, 2025 2:15am
AstraZeneca touts life-extension benefit for Tagrisso combo
Jul 21, 2025 2:59pm
FDA signs off on AZ spinout Dizal's lung cancer drug Zegfrovy
Jul 7, 2025 11:28am
ASCO: J&J captures 'Breathtaking Moments' at Chicago skyscraper
Jun 3, 2025 11:00am
J&J combo survival win signals new era in EGFR lung cancer
Mar 26, 2025 11:45am
